On the lack of demonstrated clinical benefit of neoadjuvant cisplatinum therapy for cervical cancer

Roger A. Potish, Leo B. Twiggs

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: This study ascertains the benefit and detriment of cis-platinum-based regimes for advanced cervical cancer using standard response parameters as well as a methodology to separate potential effects of radiosensitization and effects of control of occult systemic metastases. Materials and Methods: In addition to conventional response criteria used to analyze three recently published randomized studies, the efficacy of neoadjuvant chemotherapy is measured with a statistical model to calculate potential improvement in survival offered by perfect local and distant control. Results: Neoadjuvant chemotherapy either did not affect or it impaired survival in the three trials. Evidence of altered failure patterns was obtained. In particular, local control was compromised by neoadjuvant chemotherapy. Conclusion: Failure patterns are altered by treatment as well as by standard prognostic factors. Neoadjuvant chemotherapy may decrease survival. Possible reasons include the limited efficacy of cis-platinum alone and in combination with other therapeutic agents, accelerated repopulation caused by neoadjuvant therapy, delay in initiation of radiotherapy by neoadjuvant chemotherapy, low statistical power of published studies, and tumor heterogeneity. Curative modalities such as surgery and radiotherapy must not be compromised by neoadjuvant chemotherapy.

Original languageEnglish
Pages (from-to)975-979
Number of pages5
JournalInternational journal of radiation oncology, biology, physics
Volume27
Issue number4
DOIs
StatePublished - Nov 15 1993
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
chemotherapy
Uterine Cervical Neoplasms
therapy
cancer
Drug Therapy
Cisplatin
radiation therapy
platinum
Radiotherapy
metastasis
Statistical Models
surgery
tumors
methodology
Neoplasm Metastasis
Therapeutics
Neoplasms

Keywords

  • Accelerated repopulation
  • Cervix cancer
  • Cis-platinum

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

On the lack of demonstrated clinical benefit of neoadjuvant cisplatinum therapy for cervical cancer. / Potish, Roger A.; Twiggs, Leo B.

In: International journal of radiation oncology, biology, physics, Vol. 27, No. 4, 15.11.1993, p. 975-979.

Research output: Contribution to journalArticle

@article{c18c68713ab8402183c1b286c7e64190,
title = "On the lack of demonstrated clinical benefit of neoadjuvant cisplatinum therapy for cervical cancer",
abstract = "Purpose: This study ascertains the benefit and detriment of cis-platinum-based regimes for advanced cervical cancer using standard response parameters as well as a methodology to separate potential effects of radiosensitization and effects of control of occult systemic metastases. Materials and Methods: In addition to conventional response criteria used to analyze three recently published randomized studies, the efficacy of neoadjuvant chemotherapy is measured with a statistical model to calculate potential improvement in survival offered by perfect local and distant control. Results: Neoadjuvant chemotherapy either did not affect or it impaired survival in the three trials. Evidence of altered failure patterns was obtained. In particular, local control was compromised by neoadjuvant chemotherapy. Conclusion: Failure patterns are altered by treatment as well as by standard prognostic factors. Neoadjuvant chemotherapy may decrease survival. Possible reasons include the limited efficacy of cis-platinum alone and in combination with other therapeutic agents, accelerated repopulation caused by neoadjuvant therapy, delay in initiation of radiotherapy by neoadjuvant chemotherapy, low statistical power of published studies, and tumor heterogeneity. Curative modalities such as surgery and radiotherapy must not be compromised by neoadjuvant chemotherapy.",
keywords = "Accelerated repopulation, Cervix cancer, Cis-platinum",
author = "Potish, {Roger A.} and Twiggs, {Leo B.}",
year = "1993",
month = "11",
day = "15",
doi = "10.1016/0360-3016(93)90477-D",
language = "English",
volume = "27",
pages = "975--979",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - On the lack of demonstrated clinical benefit of neoadjuvant cisplatinum therapy for cervical cancer

AU - Potish, Roger A.

AU - Twiggs, Leo B.

PY - 1993/11/15

Y1 - 1993/11/15

N2 - Purpose: This study ascertains the benefit and detriment of cis-platinum-based regimes for advanced cervical cancer using standard response parameters as well as a methodology to separate potential effects of radiosensitization and effects of control of occult systemic metastases. Materials and Methods: In addition to conventional response criteria used to analyze three recently published randomized studies, the efficacy of neoadjuvant chemotherapy is measured with a statistical model to calculate potential improvement in survival offered by perfect local and distant control. Results: Neoadjuvant chemotherapy either did not affect or it impaired survival in the three trials. Evidence of altered failure patterns was obtained. In particular, local control was compromised by neoadjuvant chemotherapy. Conclusion: Failure patterns are altered by treatment as well as by standard prognostic factors. Neoadjuvant chemotherapy may decrease survival. Possible reasons include the limited efficacy of cis-platinum alone and in combination with other therapeutic agents, accelerated repopulation caused by neoadjuvant therapy, delay in initiation of radiotherapy by neoadjuvant chemotherapy, low statistical power of published studies, and tumor heterogeneity. Curative modalities such as surgery and radiotherapy must not be compromised by neoadjuvant chemotherapy.

AB - Purpose: This study ascertains the benefit and detriment of cis-platinum-based regimes for advanced cervical cancer using standard response parameters as well as a methodology to separate potential effects of radiosensitization and effects of control of occult systemic metastases. Materials and Methods: In addition to conventional response criteria used to analyze three recently published randomized studies, the efficacy of neoadjuvant chemotherapy is measured with a statistical model to calculate potential improvement in survival offered by perfect local and distant control. Results: Neoadjuvant chemotherapy either did not affect or it impaired survival in the three trials. Evidence of altered failure patterns was obtained. In particular, local control was compromised by neoadjuvant chemotherapy. Conclusion: Failure patterns are altered by treatment as well as by standard prognostic factors. Neoadjuvant chemotherapy may decrease survival. Possible reasons include the limited efficacy of cis-platinum alone and in combination with other therapeutic agents, accelerated repopulation caused by neoadjuvant therapy, delay in initiation of radiotherapy by neoadjuvant chemotherapy, low statistical power of published studies, and tumor heterogeneity. Curative modalities such as surgery and radiotherapy must not be compromised by neoadjuvant chemotherapy.

KW - Accelerated repopulation

KW - Cervix cancer

KW - Cis-platinum

UR - http://www.scopus.com/inward/record.url?scp=0027440675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027440675&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(93)90477-D

DO - 10.1016/0360-3016(93)90477-D

M3 - Article

C2 - 8244832

AN - SCOPUS:0027440675

VL - 27

SP - 975

EP - 979

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -